PHILADELPHIA — Pharmaceutical industry veteran Ernest Sabo plans to retire from Lannett Co. next year.
The generic pharmaceutical company said late Monday that Sabo, vice president of regulatory affairs and chief compliance officer, is slated to retire effective Jan. 2, 2015.
Sabo joined Lannett in March 2005 as director of quality assurance (QA) and in May 2008 was promoted to vice president of regulatory affairs and corporate compliance officer.
"Ernie has been integral part of our team since joining Lannett in 2005," stated Arthur Bedrosian, president and chief executive officer of Lannett. "Importantly, during his tenure, FDA inspections for cGMP of our manufacturing facilities have been positive, which is quite a feat given the FDA’s increased scrutiny and more stringent quality-control standards. We wish Ernie well in his retirement."
Before coming to Lannett, Sabo served as manager of QA compliance from 2001 to 2003 and as associate director of QA compliance from 2003 to 2005 at Wyeth Pharmaceuticals (now part of Pfizer). Prior to that, he held positions including director of validation, quality assurance, quality control, and research and development at Delavau/Accucorp Inc. from 1993 to 2001.
Sabo has more than 30 years of experience in the pharmaceutical industry, with his background spanning quality assurance and control, cleaning/process validation and manufacturing turnkey operations.
